Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Capturing and creating value 
with biomarkers 
ACI Biomarker Utilisation & Commercialisation conference 
Dean Griffiths Ph...
Introduction to Cambridge Consultants - A world leader in technology and product innovation 
 Established out of The Univ...
Summary 
Understand user needs 
Solutions require 
biomarker and platform 
Enable solutions which 
scale 
5 September 2014...
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Researchers, clinicians and consumers 
5 September 2014 5 S4998-P-634 v1.0
Data, therapies and advice 
5 September 2014 6 S4998-P-634 v1.0
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Creating value by aligning to user needs 
5 September 2014 8 S4998-P-634 v1.0
Creating value by aligning to user needs 
Biomarkers are not new; 
"Shushrut statue" by Alokprasad at en.wikipedia 
5 Sept...
Creating value by aligning to user needs 
The need for biomarkers is growing as more targeted cancer therapies increase 
t...
Although many targeted cancer therapies still lack biomarkers 
16% 
48% 
2008 2013 
37% 
Drugs with FDA-approved 
CDx 
Dru...
Creating value by aligning to user needs 
5 September 2014 12 S4998-P-634 v1.0
Creating value by aligning to user needs 
5 September 2014 13 S4998-P-634 v1.0
Creating value by aligning to user needs 
Where are the tumour cells? 
Folate receptor-α 
targeted fluorescent agent 
Van ...
Creating value by aligning to user needs 
Where are the tumour cells? 
Folate receptor-α 
targeted fluorescent agent 
Van ...
Creating value by aligning to user needs 
Biomarkers used in vivo can detect more tumours 
Van Dam et al Nature Medicine 
...
Creating value by aligning to user needs 
Multiple companies are already active in this space 
5 September 2014 17 S4998-P...
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Enabling user adoption 
5 September 2014 19 S4998-P-634 v1.0
Enabling user adoption 
Demonstrate utility 
Image: Illumina 
5 September 2014 20 S4998-P-634 v1.0
Enabling user adoption 
Enable users to be able to access the platform and biomarkers 
The Economist 
5 September 2014 21 ...
Enabling user adoption 
Ensure that the platform and biomarker are easy to use and interpret 
Image: Illumina 
5 September...
Enabling user adoption 
Information not just data 
Image: Illumina 
5 September 2014 23 S4998-P-634 v1.0
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Scaling user adoption 
Scale is king 
5 September 2014 25 S4998-P-634 v1.0
Scaling user adoption 
5 September 2014 26 S4998-P-634 v1.0
Scaling user adoption 
Decrease barriers to entry 
Image: Abcam 
5 September 2014 27 S4998-P-634 v1.0
Scaling user adoption 
Increase data confidence 
Image: Abcam 
5 September 2014 28 S4998-P-634 v1.0
Scaling user adoption 
Generate publicity and goodwill 
Image: Abcam 
5 September 2014 29 S4998-P-634 v1.0
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Where next for biomarkers 
New analytes 
Image: Senior Airman Sandra Welch 
5 September 2014 31 S4998-P-634 v1.0
Where next for biomarkers 
Non-invasive 
5 September 2014 32 S4998-P-634 v1.0
Where next for biomarkers 
Predictive 
Image: Sgt Eric T. Sheler - USAF 
5 September 2014 33 S4998-P-634 v1.0
Agenda 
1 How do users benefit from biomarkers? 
2 Creating value by aligning to user needs 
3 Enabling user adoption 
4 S...
Summary 
Understand user needs 
Solutions require 
biomarker and platform 
Enable solutions which 
scale 
5 September 2014...
Dean.Griffiths@Cambridgeconsultants.com 
+44 1223 392139 
Cambridge UK 
Registered No. 1036296 England 
Boston USA Singapo...
Upcoming SlideShare
Loading in …5
×

Creating and capturing value with biomarkers

743 views

Published on

Talk presented at ACI Biomarker Utilisation & Commercialisation conference 2014.

Talk provides an overview of the key considerations in developing and launching biomarkers and the associated platforms.

Published in: Business
  • Be the first to comment

  • Be the first to like this

Creating and capturing value with biomarkers

  1. 1. Capturing and creating value with biomarkers ACI Biomarker Utilisation & Commercialisation conference Dean Griffiths PhD 5 September 2014 S4998-P-634 v1.0
  2. 2. Introduction to Cambridge Consultants - A world leader in technology and product innovation  Established out of The University of Cambridge in 1960  Approximately 430 scientists and engineers  For clients globally, we – design and develop breakthrough products – create and license intellectual property – provide business consulting in technology critical issues 5 September 2014 2 S4998-P-634 v1.0
  3. 3. Summary Understand user needs Solutions require biomarker and platform Enable solutions which scale 5 September 2014 3 S4998-P-634 v1.0
  4. 4. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 4 S4998-P-634 v1.0
  5. 5. Researchers, clinicians and consumers 5 September 2014 5 S4998-P-634 v1.0
  6. 6. Data, therapies and advice 5 September 2014 6 S4998-P-634 v1.0
  7. 7. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 7 S4998-P-634 v1.0
  8. 8. Creating value by aligning to user needs 5 September 2014 8 S4998-P-634 v1.0
  9. 9. Creating value by aligning to user needs Biomarkers are not new; "Shushrut statue" by Alokprasad at en.wikipedia 5 September 2014 9 S4998-P-634 v1.0
  10. 10. Creating value by aligning to user needs The need for biomarkers is growing as more targeted cancer therapies increase their market share Reproduced from (Aitken, 2014) 5 September 2014 10 S4998-P-634 v1.0
  11. 11. Although many targeted cancer therapies still lack biomarkers 16% 48% 2008 2013 37% Drugs with FDA-approved CDx Drugs with FDA-approved biomarkers Other Drugs Creating value by aligning to user needs 13% 57% 30% Cambridge Consultants analysis 2014 5 September 2014 11 S4998-P-634 v1.0
  12. 12. Creating value by aligning to user needs 5 September 2014 12 S4998-P-634 v1.0
  13. 13. Creating value by aligning to user needs 5 September 2014 13 S4998-P-634 v1.0
  14. 14. Creating value by aligning to user needs Where are the tumour cells? Folate receptor-α targeted fluorescent agent Van Dam et al Nature Medicine 17, 1315–1319 (2011) 5 September 2014 14 S4998-P-634 v1.0
  15. 15. Creating value by aligning to user needs Where are the tumour cells? Folate receptor-α targeted fluorescent agent Van Dam et al Nature Medicine 17, 1315–1319 (2011) 5 September 2014 15 S4998-P-634 v1.0
  16. 16. Creating value by aligning to user needs Biomarkers used in vivo can detect more tumours Van Dam et al Nature Medicine 17, 1315–1319 (2011) 5 September 2014 16 S4998-P-634 v1.0
  17. 17. Creating value by aligning to user needs Multiple companies are already active in this space 5 September 2014 17 S4998-P-634 v1.0
  18. 18. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 18 S4998-P-634 v1.0
  19. 19. Enabling user adoption 5 September 2014 19 S4998-P-634 v1.0
  20. 20. Enabling user adoption Demonstrate utility Image: Illumina 5 September 2014 20 S4998-P-634 v1.0
  21. 21. Enabling user adoption Enable users to be able to access the platform and biomarkers The Economist 5 September 2014 21 S4998-P-634 v1.0
  22. 22. Enabling user adoption Ensure that the platform and biomarker are easy to use and interpret Image: Illumina 5 September 2014 22 S4998-P-634 v1.0
  23. 23. Enabling user adoption Information not just data Image: Illumina 5 September 2014 23 S4998-P-634 v1.0
  24. 24. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 24 S4998-P-634 v1.0
  25. 25. Scaling user adoption Scale is king 5 September 2014 25 S4998-P-634 v1.0
  26. 26. Scaling user adoption 5 September 2014 26 S4998-P-634 v1.0
  27. 27. Scaling user adoption Decrease barriers to entry Image: Abcam 5 September 2014 27 S4998-P-634 v1.0
  28. 28. Scaling user adoption Increase data confidence Image: Abcam 5 September 2014 28 S4998-P-634 v1.0
  29. 29. Scaling user adoption Generate publicity and goodwill Image: Abcam 5 September 2014 29 S4998-P-634 v1.0
  30. 30. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 30 S4998-P-634 v1.0
  31. 31. Where next for biomarkers New analytes Image: Senior Airman Sandra Welch 5 September 2014 31 S4998-P-634 v1.0
  32. 32. Where next for biomarkers Non-invasive 5 September 2014 32 S4998-P-634 v1.0
  33. 33. Where next for biomarkers Predictive Image: Sgt Eric T. Sheler - USAF 5 September 2014 33 S4998-P-634 v1.0
  34. 34. Agenda 1 How do users benefit from biomarkers? 2 Creating value by aligning to user needs 3 Enabling user adoption 4 Scaling user adoption 5 Where next for biomarkers 6 Summary 5 September 2014 Commercially Confidential 34 S4998-P-634 v1.0
  35. 35. Summary Understand user needs Solutions require biomarker and platform Enable solutions which scale 5 September 2014 35 S4998-P-634 v1.0
  36. 36. Dean.Griffiths@Cambridgeconsultants.com +44 1223 392139 Cambridge UK Registered No. 1036296 England Boston USA Singapore www.CambridgeConsultants.com Cambridge Consultants is part of the Altran group, a global leader in Innovation. www.Altran.com The contents of this presentation are commercially confidential and the proprietary information of Cambridge Consultants © 2014 Cambridge Consultants Ltd. All rights reserved. 5 September 2014 S4998-P-634 v1.0

×